公开(公告)号：US20180311381A1

公开(公告)日：2018-11-01

申请号：US15790246

申请日：2017-10-23

Applicant: ModernaTX, Inc.

Inventor： Stephane BANCEL ,  Tirtha CHAKRABORTY ,  Antonin DE FOUGEROLLES ,  Sayda M. ELBASHIR ,  Matthias JOHN ,  Atanu ROY ,  Susan WHORISKEY ,  Kristy M. WOOD ,  Paul HATALA ,  Jason P. SCHRUM ,  Kenechi EJEBE ,  Jeff Lynn ELLSWORTH ,  Justin GUILD

IPC: A61K48/00 ,  C12P21/00 ,  C12P13/04 ,  C12N15/87 ,  C12N15/85 ,  C12N15/52 ,  C12N15/11 ,  C12N9/00 ,  C12N9/88 ,  C12N9/64 ,  C12N9/68 ,  C12N9/42 ,  C12N9/24 ,  C12N9/16 ,  C12N9/12 ,  C12N9/10 ,  C12N9/02 ,  C07K16/40 ,  C07K16/28 ,  C07K16/00 ,  C07K14/745 ,  C07K14/705 ,  C07K14/62 ,  C07K14/61 ,  C07K14/56 ,  C07K14/54 ,  C07K14/535 ,  C07K14/525 ,  C07K14/515 ,  C07K14/505 ,  C07K14/495 ,  C07K14/485 ,  C07K14/475 ,  C07K14/47 ,  C07K14/435 ,  C07K14/005 ,  C07H21/02 ,  A61K38/48 ,  A61K38/45 ,  A61K38/21 ,  A61K38/19 ,  A61K38/18 ,  A61K38/17 ,  A61K31/7115 ,  A61K9/51 ,  A61K9/14 ,  A61K9/127 ,  A61K47/54 ,  A61K38/00

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US20180256628A1

公开(公告)日：2018-09-13

申请号：US15761220

申请日：2016-10-05

Applicant: ModernaTX, Inc.

Inventor： Stephen HOGE ,  Tirtha CHAKRABORTY ,  Gilles BESIN ,  Ruchi JAIN

IPC: A61K31/7115 ,  C12N15/67 ,  A61K9/127 ,  A61K9/00 ,  C12N15/113

CPC classification number: A61K31/7115 ,  A61K9/0019 ,  A61K9/127 ,  C12N15/113 ,  C12N15/67 ,  C12N2310/141 ,  C12N2800/107 ,  C12N2800/22

Abstract: The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject. The disclosure further provides therapeutic treatment regimens designed to reduce or inhibit AD A or unwanted immune cell activation (e.g., B cell activation, cytokine secretion) in a subject being treated with mRNA-based therapeutics.

公开(公告)号：US20180170990A1

公开(公告)日：2018-06-21

申请号：US15662090

申请日：2017-07-27

Applicant: ModernaTX, Inc.

Inventor： Stephane BANCEL ,  Tirtha CHAKRABORTY ,  Antonin DE FOUGEROLLES ,  Sayda M. ELBASHIR ,  Matthias JOHN ,  Atanu ROY ,  Susan WHORISKEY ,  Paul HATALA ,  Jason P. SCHRUM ,  Kenechi EJEBE ,  Jeff Lynn ELLSWORTH ,  Justin GUILD ,  Ron WEISS ,  Kristy M. WOOD

IPC: C07K14/535 ,  A61K48/00 ,  C07K14/745 ,  C07K16/28 ,  C07K16/32 ,  C12N9/02 ,  C12N9/64 ,  A61K38/19 ,  A61K38/21 ,  A61K38/36 ,  A61K38/44 ,  A61K38/48 ,  A61K39/395 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/75 ,  A61K47/10 ,  A61K38/18 ,  A61K38/17 ,  A61K9/14 ,  C07K14/47 ,  C12N15/85 ,  A61K9/50 ,  A61K9/127

CPC classification number: C07K14/535 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/1272 ,  A61K9/1277 ,  A61K9/14 ,  A61K9/5031 ,  A61K31/7088 ,  A61K38/1767 ,  A61K38/1816 ,  A61K38/1866 ,  A61K38/191 ,  A61K38/193 ,  A61K38/212 ,  A61K38/215 ,  A61K38/36 ,  A61K38/363 ,  A61K38/44 ,  A61K38/4833 ,  A61K38/4846 ,  A61K39/3955 ,  A61K47/10 ,  A61K47/54 ,  A61K47/542 ,  A61K48/00 ,  A61K48/0033 ,  A61K48/0066 ,  A61K48/0075 ,  C07K14/47 ,  C07K14/475 ,  C07K14/505 ,  C07K14/525 ,  C07K14/56 ,  C07K14/565 ,  C07K14/745 ,  C07K14/75 ,  C07K16/2887 ,  C07K16/32 ,  C07K19/00 ,  C12N9/0069 ,  C12N9/644 ,  C12N15/85 ,  C12N15/88 ,  C12N2840/00 ,  C12Y113/12007 ,  C12Y304/21005 ,  C12Y304/21022

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.

公开(公告)号：US20170252461A1

公开(公告)日：2017-09-07

申请号：US15294034

申请日：2016-10-14

Applicant: ModernaTX, Inc.

Inventor： Tirtha CHAKRABORTY ,  Antonin DE FOUGEROLLES

IPC: A61K48/00 ,  C12N15/67 ,  A61K38/19 ,  A61K31/7115

CPC classification number: A61K48/0066 ,  A61K31/7115 ,  A61K38/193 ,  C12N15/67

Abstract: The invention relates to compositions and methods for the manufacture and optimization of modified mRNA molecules via optimization of their terminal architecture.